Mitsubishi UFJ Trust & Banking Corp Purchases 121,338 Shares of Exelixis, Inc. $EXEL

Mitsubishi UFJ Trust & Banking Corp increased its position in Exelixis, Inc. (NASDAQ:EXEL) by 107.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 234,533 shares of the biotechnology company’s stock after buying an additional 121,338 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Exelixis were worth $10,337,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Truist Financial Corp grew its holdings in Exelixis by 1.1% in the 2nd quarter. Truist Financial Corp now owns 22,292 shares of the biotechnology company’s stock worth $983,000 after acquiring an additional 250 shares during the last quarter. Frank Rimerman Advisors LLC boosted its holdings in shares of Exelixis by 4.7% during the first quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 285 shares during the period. Rathbones Group PLC grew its stake in shares of Exelixis by 5.3% in the first quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company’s stock worth $253,000 after purchasing an additional 347 shares during the last quarter. Larson Financial Group LLC increased its holdings in Exelixis by 9.2% during the 1st quarter. Larson Financial Group LLC now owns 4,367 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 367 shares during the period. Finally, Plato Investment Management Ltd raised its position in Exelixis by 6.5% during the 2nd quarter. Plato Investment Management Ltd now owns 6,174 shares of the biotechnology company’s stock valued at $271,000 after purchasing an additional 377 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In related news, Director Mary C. Beckerle sold 24,622 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the transaction, the director owned 21,380 shares of the company’s stock, valued at $896,463.40. This trade represents a 53.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Stelios Papadopoulos sold 100,000 shares of Exelixis stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total value of $4,355,000.00. Following the transaction, the director owned 1,189,228 shares of the company’s stock, valued at $51,790,879.40. The trade was a 7.76% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 173,005 shares of company stock valued at $7,443,678. Corporate insiders own 2.82% of the company’s stock.

Exelixis Trading Down 1.7%

Shares of Exelixis stock opened at $41.65 on Monday. Exelixis, Inc. has a 12 month low of $31.90 and a 12 month high of $49.62. The firm has a market capitalization of $11.17 billion, a P/E ratio of 20.02, a P/E/G ratio of 0.79 and a beta of 0.32. The business has a fifty day simple moving average of $39.47 and a two-hundred day simple moving average of $40.55.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm had revenue of $597.76 million for the quarter, compared to the consensus estimate of $590.04 million. During the same period in the prior year, the firm earned $0.47 EPS. The company’s revenue was up 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. Analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Guggenheim lowered Exelixis from a “buy” rating to a “neutral” rating in a research report on Monday, November 3rd. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. William Blair reissued an “outperform” rating on shares of Exelixis in a research report on Tuesday, July 29th. Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a report on Wednesday, October 8th. Finally, Cowen reaffirmed a “buy” rating on shares of Exelixis in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.45.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.